酪氨酸激酶抑制剂治疗非小细胞肺癌的临床应用

吉非替尼为一种选择性的EGFR一蛋白酪氨酸激酶抑制剂,能阻断酪氨酸蛋白激酶信号传导通路,从而促进肿瘤细胞凋亡。它是作为第一个用于肺癌治疗的分子靶向药物,在治疗非小细胞肺癌中拥有其自身的优越性在临床中取得了一定成效,但仍存在很多问题。本文针对吉非替尼靶向治疗非肺癌小细胞肺癌中的优点和所面临的问题进行阐述。

Clinical Application of Tyrosine Kinase Inhibitor Treating Non-small Cell Lung Cancer

Gefitinib is protein tyrosine kinase inhibitor of a selective EGFR,can block the signal transduction pathway of tyrosine protein kinase,and then promote tumor cell apoptosis.Gefitinib as molecular targeted drug is firstly used for treating lung cancer,and it has its own advantages in the treatment of non-small cell lung cancer,which achieves certain results in clinical treatment,but there still are many problems.The advantages that Gefitinib treated non-small cell lung cancer and the existing problems were expounded in this thesis.